

Press Release

C4U Corporation

## New Patent Issued in Japan (Patent No. 7752369) Expanding CRISPR-Cas3 Patent Portfolio

C4U Corporation ("C4U") is pleased to announce that the patent application for the invention "GUIDE RNA AND USE THEREOF", concerning a novel form of guide RNA used in CRISPR-Cas system and its application was issued in Japan on October 2, 2025 as Patent No. 7752369.

CRISPR-Cas system comprises Class I, which cleaves target sequences by a conformation of multiple proteins, and Class II, which cleaves target sequences via a single protein. CRISPR-Cas3, which C4U pursues to commercialize, belongs to Class I and classified as Type I CRISPR. This invention finds the structure of the guide RNA required for forming the cascade that enables the

This invention finds the structure of the guide RNA required for forming the cascade that enables the Type I CRISPR-Cas system to function. Furthermore, leveraging these discoveries enables the development of novel Type I CRISPR-Cas3 systems that can incorporate reverse transcriptase and achieve Prime Editing–like genome modifications.

C4U will continue to strengthen its intellectual property portfolio with regard to CRISPR-Cas3 technology worldwide and accelerate its application in a wide range of fields, including pharmaceutical field.

## **About C4U Corporation**

C4U is a privately held biotech company based in Osaka, Japan, and is focused on the development of safe and efficient gene therapies utilizing its proprietary next generation CRISPR-Cas3 gene editing platform. In comparison to the CRISPR-Cas9 platform, CRISPR-Cas3 presents the distinct benefits of: 1) no off-target by the higher selectivity of deletion site (improved safety); 2) efficient knockouts by the larger deletion of gene sequences; and 3) an entirely independent patent portfolio. C4U has been granted a worldwide exclusive license to CRISPR-Cas3 by the University of Osaka for use in eukaryotic cells thus simplifying sublicensing transactions which is in sharp contrast to the complex and heavily litigated CRISPR-Cas9 patent landscape.

https://www.crispr4u.jp/en/

## **Contact Information**

C4U Corporation

Address: Yamadaoka 2-8, Suita, Osaka 565-0871, Japan

E-mail: info@crispr4u.com